The PTPN11 gene encodes SHP-2, a nonreceptor protein tyrosine phosphatase that relays signals from activated growth factor receptors to p21 ras (Ras) and other signaling molecules. Somatic PTPN11 mutations are common in patients with juvenile myelomonocytic leukemia (JMML) and have been reported in some other hematologic malignancies. We analyzed specimens from 278 pediatric patients with acute myelogenous leukemia (AML) who were enrolled on Children's Cancer Group trials 2941 and 2961 for PTPN11 mutations. Missense mutations of PTPN11 were detected in 11 (4%) of these samples. None of these patients had mutations in NRAS; however, one patient had evidence of a FLT3 alteration. Four of the patients with PTPN11 mutations (36%) were boys with French-AmericanBritish (FAB) morphology M5 AML (P ¼ 0.012). Patients with mutations also presented with elevated white blood cell counts. There was no difference in clinical outcome for patients with and without PTPN11 mutations. These characteristics identify a subset of pediatric AML with PTPN11 mutations that share clinical and biologic features with JMML.
Introduction
Acute myeloid leukemia (AML) is characterized by expansion of myeloid blasts with suppression of normal hematopoiesis. Cytogenetic and molecular studies have defined AML as a heterogeneous disease comprised of genetically distinct clonal disorders. Whereas recurring chromosomal translocations are a hallmark of AML, these genetic lesions are thought to cooperate with mutations in genes that encode growth factor receptors and downstream effectors.
1 FLT3 and CKIT encode class III receptor tyrosine kinases that activate Ras and other signaling cascades. 2 Dominant activating mutations in FLT3, CKIT, NRAS, and KRAS have been reported in up to 50% of patients with AML. [2] [3] [4] Uncovering other mutations that perturb the RTK/Ras signaling pathways could further illuminate the biology of AML, provide new independent prognostic markers, and/or identify new therapeutic targets.
The PTPN11 gene encodes SHP-2, a nonreceptor protein tyrosine phosphatase that relays signals from activated growth factor receptors to Ras and other signaling molecules. 5 Germline mutations in PTPN11 are a major cause of Noonan syndrome (NS). 6, 7 Children with NS are at increased risk of developing juvenile myelomonocytic leukemia (JMML), a relentless myeloproliferative disorder characterized by overproduction of myelomonocytic cells that infiltrate spleen, liver, and skin, among other organs. [8] [9] [10] Most children with JMML are boys. [8] [9] [10] We and others have recently reported that up to 35% of patients with JMML harbor missense PTPN11 mutations, which are largely exclusive of RAS and NF1 alterations. 11, 12 All of these mutations are predicted to activate SHP-2 phosphatase activity by disrupting the inhibitory interaction between the N-SH2 and PTP domains of the protein. Although the biochemical data are inconclusive, genetic studies suggest that the hyperactive PTPN11 mutations found in JMML contribute to leukemia growth by deregulating the Ras pathway. 11, 12 Based on the existence of NRAS and KRAS mutations in AML and JMML, we reasoned that mutations in PTPN11 might also occur in both diseases. To address this question, we screened a well-characterized cohort of AML specimens from children enrolled on Children's Cancer Group (CCG) clinical trials 2941 and 2961 for mutations in PTPN11 and correlated these data with clinical and molecular data.
Materials and methods

Patients and therapy
Bone marrow specimens from 298 patients with de novo AML registered on protocols CCG 2941 and 2961 were included in this study. A total of 278 specimens had adequate DNA for analysis. The diagnosis of AML was made according to FAB classification and confirmed by central review. The treatments delivered on CCG 2941 and 2961 have been previously detailed. 13, 14 The study was approved by the UCSF Committee on Human Research and the CCG Myeloid Biology Committee.
Mutation detection
DNA was extracted from cryopreserved bone marrow cells using PureGene reagents (Gentra Systems Inc, Minneapolis, MN, USA). Methods for the mutational analysis for PTPN11, NRAS, and FLT3 internal tandem duplications (ITD) and FLT3 activating loop mutations (ALM) have been previously described. 2, 7, 12, 15 Based on the locations of mutations in NS and JMML, exons 3, 4, 5, 6, 7, 8, 11, 12, and 13 of PTPN11 were screened.
Statistical methods
Data from CCG 2941 (through March 2002) and 2961 (through January 2004) were used to compare patients who had samples analyzed for PTPN11 mutations with those who did not, and to assess the characteristics of patients with and without PTPN11 mutations. The significance of observed differences was tested using the w 2 and Fisher exact tests. For continuous data, the Mann-Whitney test was used to compare the medians of distributions. Patients who were lost to follow-up were censored at their last known point of study, with a cutoff of September 2001 (CCG 2941) or July 2003 (CCG 2961). Actuarial estimates of overall survival (OS) and event-free survival (EFS) from study entry and disease-free survival (DFS), defined as the time from achieving remission to marrow relapse or death, were estimated using the Kaplan-Meier method. 16 Corresponding standard errors were calculated using Greenwood's formula. 17 Differences in OS, EFS, and DFS were tested for significance using the log rank statistic. 18 
Results and discussion
To determine whether our study population was representative of the entire CCG-2941/2961 population (n ¼ 988), the clinical characteristics and outcome of the 278 analyzed patients were compared to the 710 patients that were not studied. There were no significant differences with respect to age, sex, race, presenting white count, hemoglobin, platelet count, or FAB morphology. Cytogenetic information was available on 549 cases (56%), including 170 that we analyzed for PTPN11 mutations. There were no significant differences with respect to the distribution of previously defined good, poor, or standard risk cytogenetics, 19 survival, or event-free survival between the study population and the rest of the patient cohort (data not shown).
We identified 11 PTPN11 mutations in the 278 analyzed patients (4.0%, 95% CI 1.7-6.2%), which are listed in Table 1 . All of the mutations encode amino-acid substitutions within the N-SH2 domain where it interacts with the PTP domain ( Table 1) . As in JMML, the majority of mutations are located in exon 3 with 'hotspots' at codons 72 and 76. 11, 12 One possible limitation of this study is that only nine of the 15 possible exons were screened; however, these are the most commonly mutated exons identified in hematopoietic disorders thus far.
Clinical characteristics of the study population are summarized in Table 2 . There were no differences in diagnostic parameters including the median age, percentage of bone marrow blasts, presence of central nervous system (CNS) disease, hemoglobin, or platelet counts of patients with and without mutations. PTPN11 mutations were more common in boys, but this was not statistically significant (5.9 vs 1.6%, P ¼ 0.119). Five of the 11 patients (46%) with PTPN11 mutations had FAB M5 morphology compared to 37/261 (14%) of those without mutations (P ¼ 0.016). Taken together, four of the 11 (36%) patients with PTPN11 mutations were boys with FAB M5 morphology. This is significantly higher than the 8% of patients without mutations (P ¼ 0.012). In addition, there was a trend for patients with PTPN11 mutations to present with a white blood cell count 4100,000 ml (P ¼ 0.102). The probabilities of achieving a first clinical remission as well as EFS and OS were similar in patients with and without PTPN11 mutations. However, the power to detect significant differences is diminished by the low frequency of mutations.
These AML samples were also analyzed for One of 11 patients with PTPN11 mutations (9%) had an internal tandem duplication of the FLT3 receptor gene compared with 17% of the rest of the cohort (P ¼ 0.808). Whereas the overall incidence of NRAS mutations was 10% in 266 analyzed samples, none of the 11 specimens with PTPN11 mutations showed an NRAS mutation (P ¼ 0.608).
PTPN11 mutations are found in B35% of JMML samples; 11, 12 however, we detected a much lower incidence in de novo pediatric AML (4%). Patients with PTPN11 mutations tend to be boys who present with markedly elevated leukocyte counts and FAB M5 leukemia. Interestingly, the rare cases of AML that evolve from JMML typically show FAB M4 or M5 morphology. The clinical and biologic similarities between JMML and pediatric AML with PTPN11 alterations raise the possibility that both of these myeloid malignancies are initiated by a PTPN11 mutation. Indeed, genetic analysis of human JMML specimens and the phenotype of Kras and Nf1 mutant mice infer that hyperactive Ras can initiate a myeloproliferative disorder. 20, 21 However, the existing data also support a model in which AML is initiated by genetic lesions leading to aberrant transcription that cooperate with mutations that deregulate signal transduction pathways. 20, 21 Consistent with this idea, three of the AML patients with PTPN11 mutations also showed recurrent leukemia-associated cytogenetic abnormalities. Other patients may have also demonstrated common cytogenetic abnormalities; however, available data for them were lacking. Rather than 28-31 They do not, however, appear to be at an increased risk of developing AML. While some of the same codons are affected in both NS and AML, many are different. The biochemical effects of these substitutions are not completely understood and it is unclear why patients with NS are not predisposed to developing AML.
The lack of NRAS mutations in pediatric AML specimens with PTPN11 mutations is consistent with the idea that PTPN11 mutations undermine myeloid growth by deregulating Ras. Similarly, PTPN11 mutations are largely restricted to JMML specimens without mutations in either RAS or NF1, which encodes a GTPase activating protein that negatively regulates Ras output. We were unable to analyze primary cells of patients with PTPN11 mutations for constitutive activation of SHP-2. Some, but not all, cultured cell lines engineered to express mutant SHP-2 proteins show hyperactive Ras signaling. 11, 12, 32 Further studies are required to address how PTPN11 mutations contribute to specific subsets of AML, and to fully characterize the biochemical consequences of leukemia-associated SHP-2 proteins in hematopoietic cells. 
